-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
1 view
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate certepetide. The United States Patent and Trademark Office (USPTO) has granted the company US Patent No 12,351,653, which provides protection for certepetide through March 2040, with the possibility of a patent term extension.
